JWH-161

JWH-161

Systematic (IUPAC) name
(4aR,13bR)-2,5,5-trimethyl-8-pentyl-3,4,4a,5,8,13b-hexahydroisochromeno[3,4-b]carbazol-13-ol
Identifiers
PubChem	CID 10431286
ChemSpider	8606713
Chemical data
Formula	C27H33NO2
Molar mass	403.555 g/mol
SMILES Oc3c5c1ccccc1n(c5cc2OC([C@@H]4CC/C(=C\[C@H]4c23)C)(C)C)CCCCC
InChI InChI=1S/C27H33NO2/c1-5-6-9-14-28-21-11-8-7-10-18(21)24-22(28)16-23-25(26(24)29)19-15-17(2)12-13-20(19)27(3,4)30-23/h7-8,10-11,15-16,19-20,29H,5-6,9,12-14H2,1-4H3/t19-,20-/m1/s1 Key:VDJUAFPNHZRTNL-WOJBJXKFSA-N
(verify)

JWH-161 is a cannabinoid derivative that was designed by Dr John W. Huffman's team as a hybrid between the dibenzopyran "classical" cannabinoid drugs and the novel indole derivatives, in an attempt to unravel the differences in their binding modes to the CB₁ receptor. While retaining structural elements from both families, JWH-161 has a CB₁ K_i of 19.0nM, although it was found to be slightly weaker than THC in animal tests.^[1]

References

1. Huffman JW, Padgett LW (2005). "Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes". Current Medicinal Chemistry 12 (12): 1395–411. doi:10.2174/0929867054020864. PMID 15974991.